GlassScriptPhysician profile
Robin L Smiddy
NPI 1659932465
$5,804.01
in general payments reported to CMS, 2019-2025
32 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $1,116 · 2023: $1,082 · 2024: $1,876 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,495 · Travel and Lodging: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,494.63 |
| Travel and Lodging | $1,020.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $2,296.90 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $488.22 | 2021-2025 | Intracept, General - Pain Management |
| Medtronic, INC. | $471.72 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Alexion Pharmaceuticals, INC. | $283.92 | 2022-2025 | Strensiq |
| Abbvie INC. | $280.69 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.05 | 2021-2024 | Caplyta |
| Vertos Medical, INC. | $200.96 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $180.24 | 2024-2025 | |
| Mml US, INC. | $167.64 | 2023-2025 | Reactiv8 |
| Azurity Pharmaceuticals, INC. | $127.77 | 2022-2025 | Horizant, Horizant |
| Lilly USA, LLC | $121.49 | 2022-2023 | Mounjaro, Zepbound, Emgality |
| Alkermes, INC. | $107.34 | 2022-2023 | Aristada, Lybalvi |
| Radius Health, INC. | $93.41 | 2022-2023 | Tymlos |
| Ibsa Pharma INC. | $80.99 | 2022-2023 | Tirosint, Licart |
| Teva Pharmaceuticals USA, INC. | $78.27 | 2022-2024 | Austedo, Austedo Xr |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $71.77 | 2021-2023 | Prolia, Evenity |
| Novo Nordisk INC | $69.33 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $61.82 | 2021-2024 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $59.41 | 2024 | |
| Lundbeck LLC | $54.27 | 2022-2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $52.76 | 2022-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $45.02 | 2021-2022 | |
| Axsome Therapeutics, INC. | $42.56 | 2022-2025 | Auvelity |
| Relievant Medsystems, INC. | $24.47 | 2022 | |
| Averitas Pharma INC. | $23.47 | 2023 | Qutenza |
| Gilead Sciences, INC. | $23.24 | 2024 | |
| Si-Bone, INC. | $18.52 | 2021 | |
| Indivior INC. | $17.55 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.65 | 2023 | Relistor |
| Neurocrine Biosciences, INC. | $15.27 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $13.16 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.13 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Smiddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.